Stock SILK SILK ROAD MEDICAL, INC
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Silk Road Medical, Inc

Equities

SILK

US82710M1009

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
18.9 USD +6.18% Intraday chart for Silk Road Medical, Inc +8.56% +54.03%
Apr. 02 Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuro Protection System Plus CI
Mar. 08 North American Morning Briefing : Stock Futures -2- DJ

Summary

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Analyst opinion has improved significantly over the past four months.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The company's enterprise value to sales, at 3.76 times its current sales, is high.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
SILK ROAD MEDICAL, INC Stock Silk Road Medical, Inc
+54.03% 745M
C
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.54% 186B
C+
MEDTRONIC PLC Stock Medtronic plc
-1.85% 107B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-4.26% 67.44B
A
DEXCOM, INC. Stock DexCom, Inc.
+1.39% 50.03B
B-
CENCORA, INC. Stock Cencora, Inc.
+16.82% 47.81B
B-
HOYA CORPORATION Stock Hoya Corporation
+4.79% 41.03B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+3.49% 26.85B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+0.65% 25.82B
A-
TERUMO CORPORATION Stock Terumo Corporation
+16.55% 24.74B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SILK Stock
  4. Ratings Silk Road Medical, Inc